Body Mass Index and Prognostic Nutritional Index as Indicators of Treatment Adherence and Survival Outcomes in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Undergoing Sequential Chemoradiotherapy - Scorecard - MDSpire
Advertisement
Body Mass Index and Prognostic Nutritional Index as Indicators of Treatment Adherence and Survival Outcomes in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Undergoing Sequential Chemoradiotherapy
Clinical Scorecard: Body Mass Index and Prognostic Nutritional Index as Indicators of Treatment Adherence and Survival Outcomes in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Undergoing Sequential Chemoradiotherapy
At a Glance
Category
Detail
Condition
Key Mechanisms
Sequential chemoradiotherapy following induction chemotherapy to improve treatment outcomes, particularly in reducing tumor size and enhancing local-regional control.
Target Population
Care Setting
Key Highlights
Head and neck cancers account for 5-6% of male cancers in the U.S., with significant mortality rates.
Induction chemotherapy may enhance the efficacy of subsequent chemoradiotherapy, particularly in advanced stages.
Toxicity from treatment can limit quality of life and survival outcomes, necessitating careful monitoring.
BMI and PNI are evaluated as predictors of treatment completion and survival, with implications for patient management.
Guideline-Based Recommendations
Diagnosis
Management
Administer three cycles of induction chemotherapy followed by concurrent chemoradiotherapy, adjusting based on patient response and toxicity.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients diagnosed with locally advanced HNSCC, excluding those with previous chemotherapy or radiotherapy, inflammatory diseases, or second malignancies.
Clinical Best Practices
Utilize a multidisciplinary approach for treatment planning, ensuring comprehensive care.
Assess inflammatory biomarkers prior to treatment to predict outcomes and tailor therapy.
Adjust chemotherapy doses according to international guidelines, considering patient-specific factors.
